LONDON: Cellular Goods PlC began taking investor orders in an initial public offering on the London Stock Exchange.
Shares in the U.K.-based company’s offering are marketed at 5 pence apiece, according to a pathfinder prospectus published Monday.
The IPO is expected to raise 8 million pounds ($11 million), with Cellular Goods looking to use proceeds to develop and launch products, Bloomberg reported.
The share sale, which includes an offering to retail investors, is expected to value Cellular Goods at about 20 million pounds. David Beckham is among the company’s stockholders and has two representatives on its board of directors.
Tennyson Securities, Novum Securities and PrimaryBid are acting as Joint Bookrunners and Corporate Brokers for the Company.
Net proceeds from the IPO will be deployed to finalise the development and launch of a range of the Company’s premium-quality consumer products based on biosynthetic cannabinoids, which is fully compliant under UK law.
The market for CBD-based products is expected to grow rapidly as cannabinoids gain wider consumer acceptance, the regulatory environment undergoes gradual change, and a rapidly growing number of scientific papers validate their potential benefits.
The US market for CBD sales is expected to exceed $20 billion by 2024, according to BDS Analytics and Arcview Market Research.
In 2019, the UK’s Centre for Medicinal Cannabis (CMC) found that 1.3 million British consumers were using CBD-based products and estimated that the market could be worth almost £1bn a year by 2025.
The same research estimated that those 1.3 million British consumers were spending over £300m annually on CBD products.
Cellular Goods was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on two product verticals: premium skincare and topical athletic recovery products. These will be made available through partnerships with leading online and physical retailers and direct to consumers through the Company’s website.
The Company has partnered with four leading biosynthetic cannabinoid producers in the US who have experience and expertise in the manufacture of these compounds through a fermentation-based process to secure a consistent supply of legally compliant raw materials.
The production of biosynthetic cannabinoids does not involve the cultivation or processing of the cannabis sativa plant.
Leave a Reply